Prevention of Recurrence of Clostridioides Difficile Colitis with Ursodeoxycholic Acid (UCDA) As a Supplement to Standard Therapy
Launched by MEDICAL COLLEGE OF WISCONSIN · Mar 13, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Prevention of Recurrence of Clostridioides Difficile Colitis with
Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy
Paraj D. Patel M.D, Daniel J. Stein, M.D, Helmut V. Ammon, MD
This proposal describes the use of UDCA as an adjunct to standard treatment of C. difficile (C. diff) colitis for the prevention of recurrence of the disease.
The Problem: C. diff colitis is a serious burden on the healthcare system. In 2011 there were close to 500,000 cases of and 29,000 deaths from C. diff. colitis reported in the US at an annual cost of 58 billion dollars \[1, 2\] Treatment cons...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Eligible patients: C. diff. toxin +ve patients \> 18 years with one or more risk factors for recurrence \[6,7\] requiring standard treatment with Flagyl, Vancomycin or fidaxomicin.
- Exclusion Criteria:
- • Life expectancy \< 6 months; fulminant colitis; ileus; decompensated liver disease; pregnancy and lactating females; Inability to give informed consent.
About Medical College Of Wisconsin
The Medical College of Wisconsin (MCW) is a leading academic institution dedicated to advancing healthcare through innovative research, education, and clinical practice. As a prominent clinical trial sponsor, MCW is committed to conducting high-quality, ethically-guided research that aims to improve patient outcomes and address critical health challenges. Leveraging a multidisciplinary approach, MCW collaborates with a diverse network of healthcare professionals, researchers, and community partners to facilitate groundbreaking clinical trials across various medical fields, ensuring the translation of scientific discoveries into effective treatments and practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milwaukee, Wisconsin, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported